What is HC Wainwright’s Estimate for Nkarta FY2025 Earnings?

Nkarta, Inc. (NASDAQ:NKTX) – Investment analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Nkarta in a note issued to investors on Thursday, May 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($1.21) per share for the year, up from their prior estimate of ($1.29). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s Q4 2025 earnings at ($0.27) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.51) EPS and FY2029 earnings at ($0.95) EPS.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01.

A number of other brokerages have also issued reports on NKTX. Needham & Company LLC decreased their target price on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, May 15th. William Blair restated a “market perform” rating on shares of Nkarta in a research report on Thursday, May 15th. Finally, Stifel Nicolaus decreased their target price on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 27th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $14.67.

Nkarta Stock Performance

Shares of NKTX opened at $1.80 on Monday. Nkarta has a 52 week low of $1.31 and a 52 week high of $8.23. The firm has a market cap of $127.72 million, a P/E ratio of -0.96 and a beta of 0.81. The firm’s 50-day simple moving average is $1.79 and its 200 day simple moving average is $2.18.

Institutional Trading of Nkarta

Several large investors have recently made changes to their positions in NKTX. Jefferies Financial Group Inc. lifted its stake in Nkarta by 901.7% in the 4th quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company’s stock valued at $6,236,000 after purchasing an additional 2,254,219 shares during the last quarter. Tang Capital Management LLC lifted its stake in Nkarta by 252.9% in the 4th quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company’s stock valued at $5,711,000 after purchasing an additional 1,643,719 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Nkarta by 138.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock valued at $6,319,000 after purchasing an additional 1,474,560 shares during the last quarter. Jane Street Group LLC lifted its stake in Nkarta by 118.7% in the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock valued at $247,000 after purchasing an additional 852,559 shares during the last quarter. Finally, Monaco Asset Management SAM bought a new position in Nkarta in the 1st quarter valued at approximately $1,496,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.